NASDAQ · Drug Manufacturers - Specialty & Generic · USD
RedHill Biopharma Ltd. (RDHL) Stock Analysis
RedHill Biopharma Ltd. (RDHL) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
RDHL Key Statistics
As of Sep 4, 2026Trading
- Open
- $0.74
- Previous Close
- $0.71
- Day's Range
- 0.70–0.77
- 52-Week Range
- 0.57–2.79
- Volume
- 575.70K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 4.95
Valuation
- Market Cap
- $4.41M
- P/E Ratio
- unprofitable
- Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
- 24.15
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 15.40
- EPS (ttm)Profit attributable to each share over the last twelve months.
- 0.00
Financials (FY)
- Revenue (FY)
- $286.00K
- Net Income (FY)
- −$429.00K
- Profit marginThe share of revenue left as profit after all costs and taxes.
- −150.00%
- Shares Outstanding
- 6.08M
- 1-Year Return
- −41.14%
Dividend and dates
- Avg Volume
- 1.95M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
RDHL Stock Return by Calendar Year
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −29.71% |
| 2025 | −83.41% |
| 2024 | −82.99% |
| 2023 | −73.93% |
| 2022 | −94.57% |
| 2021 | −68.07% |
| 2020 | +33.11% |
| 2019 | +9.37% |
| 2018 | +7.98% |
| 2017 | −50.86% |
| 2016 (partial year) | −31.81% |
As of September 4, 2026.
RDHL Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $286.00K | −$429.00K | −150.0% |
| 2024 | $0.00 | −$8.27M | — |
| 2023 | $0.00 | $23.92M | — |
| 2022 | $61.80M | −$71.67M | −116.0% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $286.00K | — | −$7.91M | −$429.00K | −150.0% |
| 2024 | $0.00 | $4.85M | −$6.48M | −$8.27M | — |
| 2023 | $0.00 | $3.07M | −$9.55M | $23.92M | — |
| 2022 | $61.80M | $28.46M | −$42.84M | −$71.67M | −116.0% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
RDHL Valuation vs Drug Manufacturers - Specialty & Generic Median
Median of 103 stocks| Metric | RDHL | Drug Manufacturers - Specialty & Generic median | vs median |
|---|---|---|---|
| P/S ratio | 15.40 | 2.30 | 6.7x the median |
| Profit margin | −150.00% | −3.14% | 146.9 pts below |
Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.
Recent News
Redhill Biopharma Stock Doubles In One Session — Here's Why
BenzingaRedhill Biopharma Divests Talicia Business To Apotex Health Subsidiary For An Upfront Payment Of $18M Plus Up To An Additional $35M In Potential Sales-based Milestone Payments
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.
Related Drug Manufacturers - Specialty & Generic Stocks
Takeda Pharmaceutical Company Limited
$58.92B
TEVATeva Pharmaceutical Industries Limited
$42.37B
HLNHaleon plc
$42.22B
ZTSZoetis Inc.
$31.33B
UTHRUnited Therapeutics Corporation
$20.91B
VTRSViatris Inc.
$19.39B
Popular Healthcare Stocks
Eli Lilly and Company
$1.02T
JNJJohnson & Johnson
$663.28B
ABBVAbbVie Inc.
$453.19B
MRKMerck & Co., Inc.
$370.89B
UNHUnitedHealth Group Incorporated
$356.47B